Triazenes pp 1-13 | Cite as

Triazenes: Synthesis and Chemical Properties

  • Keith Vaughan


It is a great pleasure to participate in this, the first international conference brought together to discuss the Chemical, Biological and Clinical Aspects of Triazenes. This paper deals mainly with the chemistry of triazenes; the biological properties of these compounds will be discussed in detail in other chapters of these proceedings. However, where appropriate, the anti-tumour activity of relevant compounds will be described briefly here.


Diazonium Salt Alkane Thiol Primary Aliphatic Amine Alkyl Sulfide Sodium Phenolate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    K. Vaughan and M.F.G. Stevens. Ghem. Soc. Review. 7, 377 (1978)CrossRefGoogle Scholar
  2. 2.
    T.P. Ahern and K. Vaughan. J. Chem. Soc. Chem. Comm. 701 (1973).Google Scholar
  3. 3.
    T.P. Ahern, H. Fong and K. Vaughan. Can. J. Chem. 55 1701 (1977).CrossRefGoogle Scholar
  4. 4.
    K. Vaughan. J. Chem. Soc. Perkin Trans. II. 17 (1977).Google Scholar
  5. 5.
    C.J. Rutty, D.R. Newell, R.B. Vincent, G. Abel, P.M. Goddard, S.J. Harland and A.H. Calvert. Brit. J. Cancer. 48, 140 (1983).Google Scholar
  6. 6.
    A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens and K. Vaughan. Tetrahedron Letters. 5041 (1978).Google Scholar
  7. 7.
    R.J. LaFrance, Y. Tang, K. Vaughan and D.L. Hooper. J. Chem. Soc. Chem. Comm. 721 (1983).Google Scholar
  8. 8.
    S.C. Cheng, L. Fernandez, J. Iley and E. Rosa. J. Chem. Res. (S). 108 (1983).Google Scholar
  9. 9.
    H.W. Manning, C.M. Hemens, R.J. LaFrance, Y. Tang and K. Vaughan. Can. J. Chem. 62, 749 (1984).CrossRefGoogle Scholar
  10. 10.
    K. Vaughan, Y. Tang, G. Llanos, J.K. Horton, R.J. Simmonds, J.A. Hickman and M.F.G. Stevens, J. Med. Chem. 21, 357 (1984).CrossRefGoogle Scholar
  11. 11.
    R.J. Simmonds and C.H. Schwalbe. Unpublished results.Google Scholar
  12. 12.
    N.W. Gibson, J. Hartley, R.J. LaFrance and K. Vaughan. Carcinogenesis. 7, 259 (1986).PubMedCrossRefGoogle Scholar
  13. 13.
    CM. Hemens, H.W. Manning, K. Vaughan, R.J. LaFrance and Y. Tang. Can. J. Chem. 62, 741 (1984).CrossRefGoogle Scholar
  14. 14.
    C.M. Hemens and K. Vaughan. J. Chem. Soc. Perkin Trans II. 11 (1986)Google Scholar
  15. 15.
    K. Vaughan, K.U.K. Gamage Nicholas, R.D. Singer, M. Roy and N.W. Gibson. Anti-Cancer Drug Design. 2, 279 (1987).PubMedGoogle Scholar
  16. 16.
    M. Overton, J.A. Hickman, M.D. Threadgill, K. Vaughan and A. Gescher. Biochem. Pharmacol. 34, 2055 (1985).PubMedCrossRefGoogle Scholar
  17. 17.
    R.J. LaFrance, H.W. Manning and K. Vaughan. J. Org. Chem. 50. 2229 (1985).CrossRefGoogle Scholar
  18. 18.
    R.D. Singer, K. Vaughan and D.L. Hooper. Can. J. Chem. 64, 1567 (1986).CrossRefGoogle Scholar
  19. 19.
    L.M. Cameron, R.J. LaFrance, C.M. Hemens, K. Vaughan, R. Rajaraman, D.C Chubb and P.M. Goddard. Anti-Cancer Drug Design. 1, 27 (1985).PubMedGoogle Scholar
  20. 20.
    J. Iley, E. Rosa and L. Fernandes. J. Chem. Res. (S). 264 (1987).Google Scholar
  21. 21.
    K. Vaughan, H.W. Manning, M.P. Merrin and D.L. Hooper. Can. J. Chem. 66, 2487 (1988).CrossRefGoogle Scholar
  22. 22.
    M.P. Merrin, R.J. LaFrance and K. Vaughan. Unpublished results.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Keith Vaughan
    • 1
  1. 1.Department of ChemistrySaint Mary’s UniversityHalifaxCanada

Personalised recommendations